PTC Therapeutics, Inc.
PTCT
$66.71
$2.223.44%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -22.75% | 7.23% | -4.19% | 459.73% | -30.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -22.75% | 7.23% | -4.19% | 459.73% | -30.58% |
| Cost of Revenue | -0.69% | -32.70% | -15.77% | -6.90% | -6.26% |
| Gross Profit | -65.89% | 287.62% | 39.63% | 1,230.31% | -53.94% |
| SG&A Expenses | 14.40% | 14.42% | 22.68% | 10.49% | 11.00% |
| Depreciation & Amortization | 182.70% | 148.16% | 41.75% | -92.63% | -95.71% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.53% | -16.58% | -2.88% | -19.20% | -24.64% |
| Operating Income | -414.30% | 106.71% | -4.50% | 2,228.29% | -608.69% |
| Income Before Tax | -46.87% | 76.45% | 17.12% | 1,197.84% | 39.70% |
| Income Tax Expenses | 85.71% | -549.84% | -146.13% | 819.56% | -2,188.56% |
| Earnings from Continuing Operations | -104.85% | 114.90% | 34.61% | 1,046.28% | 57.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -104.85% | 114.90% | 34.61% | 1,046.28% | 57.71% |
| EBIT | -414.30% | 106.71% | -4.50% | 2,228.29% | -608.69% |
| EBITDA | -654.61% | 132.10% | -3.55% | 9,824.03% | -110.86% |
| EPS Basic | -95.99% | 114.61% | 35.81% | 1,026.68% | 58.65% |
| Normalized Basic EPS | -426.26% | 69.23% | 7.71% | 1,164.64% | 266.28% |
| EPS Diluted | -95.99% | 114.04% | 35.79% | 936.67% | 58.65% |
| Normalized Diluted EPS | -426.26% | 72.28% | 7.71% | 1,062.71% | 266.28% |
| Average Basic Shares Outstanding | 4.52% | 2.01% | 1.86% | 2.12% | 2.27% |
| Average Diluted Shares Outstanding | 4.52% | 13.25% | 1.86% | 12.93% | 2.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |